General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1. At a Glance
Transchem Limited reported revenue from operations of ₹0.00 crore for the three months to June 2026. The line carries a dash, and has carried one for most of the past decade.
Other income was ₹5.11 crore, the largest quarterly figure in the company’s recent record. Total expenses came to ₹0.76 crore. Net profit was ₹3.42 crore, against ₹0.99 crore in the three months to June 2025. That is a quarterly profit variation of 245 per cent at a company that sold nothing. Basic earnings per share were ₹2.79 and diluted earnings per share were ₹0.57. Earnings per share is the profit divided by the number of shares.
A good deal happened around that arithmetic. In June 2026 the company allotted 6.15 crore warrants at ₹75 each. A warrant is a right to buy a share later at a fixed price. Gross potential from them is ₹461.25 crore, against a market capitalisation of ₹395 crore.
On 17 August 2026 the company completed the purchase of a stockbroker for ₹25.91 crore in cash. On 10 August the board approved the quarter’s results. In the same sitting it approved version 3.0 of the company’s insider-trading code.
The company spent roughly thirty years growing mushrooms. It now has a whole-time director, ten permanent employees as at March 2025, and a loan book.
2. Introduction
Transchem Limited was incorporated in Maharashtra in 1976, and its corporate identity number wears the date openly. For most of its listed life the company grew and exported mushrooms. It ran a 100 per cent export oriented unit for mushroom cultivation and processing.
The plant then stopped operating for several years. The filings attribute this to changes in the international horticulture market, which is how corporate India says the mushrooms stopped selling.
The exit was total. The entire undertaking was sold for ₹26 crore, with the sale deed registered on 17 June 2020. That covered land at Bebadohol and Urse villages in Maval, Pune, along with buildings, machinery and fixtures. The filings then note that manufacturing, capacity and export metrics ceased to be applicable. Few companies get to formally retire an entire vocabulary.
Five years followed in which a listed entity earned from inter-corporate deposits and treasury investments. An inter-corporate deposit is a loan from one company to another. Net profit in the year to March 2021 was ₹24.15 crore, arriving alongside other income of ₹26.82 crore. The five years from March 2022 to March 2026 ran at ₹2.87 crore, ₹1.24 crore, ₹4.20 crore, ₹5.23 crore and ₹4.30 crore.
In October 2025 shareholders amended the main objects clause, which is the list of activities a company is permitted to undertake. The new list covers securities, commodity and currency broking, margin financing and depository-participant services. It also covers investment research and advisory, portfolio services, fund management and financial technology platforms. That is a wide net for a company whose previous object clause involved a fungus. The commercial financial-services operations had not commenced by March 2026.
Then came the funding. An extraordinary general meeting on 20 December 2025 approved an increase in authorised capital and up to 6.15 crore preferential warrants. BSE granted in-principle approval on 21 May 2026. Allotment followed on 3 June 2026, with 4.75 crore of those warrants going to Bakkt Opco Holdings LLC.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3. Business Model: WTF Do They Even Do?
Presently: very little, extremely profitably.
Revenue from operations was nil in the three months to June 2026, and ₹0.00 crore in the year to March 2026. The disclosed revenue mix for that year was interest on inter-corporate deposits at 83 per cent and profit on a property sale at 17 per cent. That describes lending money and selling land, neither of which the profit and loss account is willing to call sales.
The model, stated plainly, has been to hold cash, lend it to corporates and collect the interest. The interest is booked as other income, tax is paid, and the cycle repeats. Cash and bank balances stood at ₹42.43 crore at March 2026. Other assets, the line that absorbs everything a balance sheet would rather not itemise, stood at ₹85.74 crore of an ₹87.73 crore total.
The disclosed loan book of inter-corporate deposits outstanding was ₹3,200 lakh at March 2025, against ₹6,500 lakh a year earlier. The investment portfolio was ₹203.57 lakh across nine holdings. Nine holdings and ten permanent employees works out at comfortably under one holding per person, a ratio most asset managers can only dream about.
The new model arrived on 17 August 2026. Transchem completed the acquisition of all of Greshma Shares & Stocks Limited for ₹25.91 crore in cash, making it a wholly owned subsidiary. The purchase followed approvals from the stock exchanges, the clearing corporation, CDSL and SEBI.
Greshma is a member of NSE’s cash and derivatives segments and of BSE’s cash segment. It is also
